Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Severe Sepsis Clinical Trial

— ReActIF- LTO  

Official title:

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06143137
• Other study ID #: ReActIF-ICE-LTO_ZKSJ0154
• Status: Recruiting
• Start date: November 20, 2023
• Est. completion date: February 28, 2030

Study information

• Verified date: August 2023
• Source: Artcline GmbH
• Contact: Erdmann J Zippel, RN
• Phone: +4915772371146
• Email: erdmann.zippel[@]artcline.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Description:

Sepsis is a worldwide health threat because of high mortality and the development of long-lasting disabilities, including physical and cognitive impairment and mental disorders, known collectively as post-intensive care syndrome (PICS), which contribute to reduced health-related quality of life (HRQoL) for several years even after successful recovery from the initial acute sepsis state. Sepsis survivors often need a longer period of rehabilitation, consuming more medical and social resources and struggle with financial burdens.

In the ReActIF-ICE study, that started enrolling patients in July 2022, up to 142 subjects with severe sepsis are to be enrolled and randomized into a therapy group (receiving the ARTICE treatment (extracorporeal immune cell plasma perfusion) on top of standard care) and control group (standard care only). These subjects were followed up according the ReActIF-ICE study protocol for 90 days.

Since there is still a large need for long-term outcome data of sepsis patients, collecting data of the ReActIF-ICE patients over a longer period of time would provide important additional information regarding:

1. General long term clinical and socio-economic outcome of sepsis survivors

2. Long-term outcome details of the ReActIF-ICE patient population

3. The potential long-term medical outcome effects of the additional ARTICE treatment compared to standard treatment alone.

4. The potential long-term health-related quality-of-life effects of ReActIF-ICE patient population

5. The potential long-term health-related quality-of-life effects of the additional ARTICE treatment compared to standard treatment alone.

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 142
• Est. completion date: February 28, 2030
• Est. primary completion date: December 31, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent.

2. Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial.

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Sepsis
• Severe Sepsis

Locations

Country	Name	City	State
Germany	Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin	Magdeburg
Germany	Universitätsmedizin Rostock, Abteilung KAI	Rostock

Sponsors (2)

Lead Sponsor	Collaborator
Artcline GmbH	ZKS Jena

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Long term outcome after severe sepsis	Outcome evaluation parameters; Survival rates at 6 months,1,2,3,4,5 years; Serious Adverse Events rate during the 5 year follow up period	5 years